Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Flexi Cap Fund median (49 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI - Flexi Cap Fund. |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹101.72 |
| 12 Apr 2015 | ₹160.32 |
| 31 May 2016 | ₹149.50 |
| 19 Jul 2017 | ₹168.78 |
| 07 Sep 2018 | ₹201.33 |
| 27 Oct 2019 | ₹189.58 |
| 15 Dec 2020 | ₹246.64 |
| 03 Feb 2022 | ₹326.44 |
| 25 Mar 2023 | ₹271.17 |
| 12 May 2024 | ₹345.09 |
| 01 Jul 2025 | ₹419.50 |
| 20 Aug 2026 | ₹428.62 |
| Metric | UTI · Direct · IDCW NAV ₹240.20 Very High risk ★★★☆☆ | Category median Flexi Cap Fund · 49 funds |
|---|---|---|
| +2.44% | +2.34% | |
| +10.94% | +12.85% | |
| +6.44% | +10.36% | |
| +10.56% | +8.08% | |
| +11.27% | +11.66% | |
| +8.81% | — | |
| +11.43% | +12.67% | |
| +11.72% | +11.75% | |
| +11.24% | +9.39% | |
| Risk | ||
| 12.89% | 14.56% | |
| 0.34 | 0.38 | |
| 0.48 | 0.50 | |
| -33.86% | -33.86% | |
| Nifty 500 | — | |
| -0.60% | +0.65% | |
| 0.87 | 0.98 | |
| 86.8% | 100.2% | |
| 85.8% | 97.9% | |
| 1.05% | 0.86% | |
| ₹22,328Cr | ₹4,009Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 10% | 37% | |
| Kamal Gada | — | |
| 02 Jan 2013 | — | |
| 56 | — | |
| 44.4% | — | |
| 2.7% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.